Harnessing the Therapeutic Potential of Mitochondrial DNA

Mitochondrially encoded peptides with significant impacts on systemic pathways are the foundation for the development of CohBar’s potential breakthrough therapeutics targeting chronic and age-related diseases such as NASH, obesity, fibrotic diseases, acute respiratory distress syndrome (ARDS), cancer, type 2 diabetes, and cardiovascular and neurodegenerative diseases.

What are mitochondria?

Mitochondria are generally understood to be the powerhouses of our cells and responsible for converting nutrients into energy. Mitochondria evolved and originated by endosymbiosis when a bacterium was captured by a eukaryotic cell millions of years ago. They also have their own DNA that encodes hundreds of peptides (small proteins). The mitochondrial genome is 200,000 times smaller than the nuclear genome and is inherited maternally.

A much broader role for mitochondria: recent research reveals

  • Signaling within and between cells
  • Orchestrating multiple biological systems
  • Regulating metabolism and the immune system
  • Controlling cell cycle, cell growth, and cell death (apoptosis)